Pay in 4 interest-free payments of $6.31 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
In a randomized, single-blind, 24-week study, participants assigned to dual therapy of 2 mg weekly of the GLP-1 receptor agonist exenatide (Bydureon, AstraZeneca) and 10 mg daily of the SGLT2 inhibitor dapagliflozin (Farxiga, AstraZeneca) lost more weight than those taking either agent alone or those receiving dapagliflozin and metformin extended-release (Xigduo XL, AstraZeneca) or phentermine/topiramate extended-release (Qsymia, Vivus)
For women who have seen their weight become harder to manage precisely when their health is more at risk, this is what progress could look like, said Rachel Batterham, Lilly senior vice president of medical innovation and external engagement
Start a free trial or schedule a personalized demo to see how OptiMantra can support your medical weight loss programtoday and as the market continues to evolve
Are there any toppings I should absolutely avoid
It is the first late-stage data on retatrutide, which works differently from existing injections and appears to be more effective
See a summary of the most common side effects below
